What Is Retatrutide?
Retatrutide (LY3437943) is an investigational once-weekly subcutaneous injection being developed by Eli Lilly and Company. Unlike semaglutide (a GLP-1 receptor agonist) or tirzepatide (a GIP/GLP-1 dual agonist), retatrutide simultaneously activates three hormone receptors:
- GLP-1 receptor (GLP-1R): Reduces appetite, slows gastric emptying, stimulates insulin secretion
- GIP receptor (GIPR): Enhances GLP-1-mediated effects, may reduce nausea, promotes fat utilization
- Glucagon receptor (GCGR): Increases energy expenditure, promotes lipolysis (fat breakdown), and appears to amplify weight loss beyond what GLP-1/GIP dual agonism achieves
The triple mechanism is the key differentiator. Adding glucagon receptor agonism on top of GIP/GLP-1 is hypothesized to increase the resting metabolic rate and accelerate fat oxidation — producing weight loss that may exceed what dual agonism can achieve alone. Phase 2 data appears to support this hypothesis.
Why Is Retatrutide Expected to Outperform Tirzepatide?
The Phase 2 trial (published in NEJM in 2023) reported a mean weight loss of 24.2% at the 12 mg dose at 48 weeks in participants with obesity without type 2 diabetes. To put this in context:
- Semaglutide 2.4 mg (STEP-1): 14.9% at 68 weeks
- Tirzepatide 15 mg (SURMOUNT-1): 22.5% at 72 weeks
- Retatrutide 12 mg (Phase 2): 24.2% at 48 weeks
The Phase 2 comparison is not head-to-head and the populations differ — but the signal is unmistakable. The Phase 3 TRIUMPH-4 trial (obesity with knee osteoarthritis) reported 28.7% mean weight loss at 68 weeks on the 12 mg dose — the highest ever reported for a once-weekly subcutaneous injection in a pivotal-scale trial.
Mechanistically, the glucagon receptor component is believed to be the key driver of the incremental efficacy. Glucagon typically raises blood glucose, but in the context of GLP-1 receptor coactivation (which suppresses glucagon's glucose-raising effect), the net result appears to be enhanced fat mobilization and thermogenesis without significant glycemic risk.
TRIUMPH Trial Program Status
Eli Lilly is conducting the TRIUMPH (Tirzepatide Retatrutide Investigation of Uncommon Mechanisms and Pharmacology for Health) Phase 3 program across four major trials. See our TRIUMPH trial tracker for current status of each study.
| Trial | Population | Status | Key Endpoint |
|---|---|---|---|
| TRIUMPH-1 | Obesity (incl. OSA + OA subsets) | Active | Primary completion April 2026 |
| TRIUMPH-2 | Type 2 diabetes + obesity | Active | HbA1c reduction + weight loss |
| TRIUMPH-3 | Obesity + CV disease | Active | Readout est. 2026–2027 |
| TRIUMPH-4 | Obesity + knee OA | Data Reported | 28.7% weight loss at 68 wks (Dec 2025) |
Projected FDA Approval Timeline: 2027–2028
Based on the Phase 3 timeline and typical FDA review periods, analysts and Eli Lilly's own investor communications have suggested a potential NDA (New Drug Application) submission in 2026–2027, with FDA approval potentially following in 2027–2028. Key milestones to watch:
- TRIUMPH-1 and TRIUMPH-2 completion: Full data from all trials needed for submission
- NDA submission: Analyst consensus projects Q1–Q2 2027, pending TRIUMPH-1/2 primary completion in April 2026 (analyst estimate, not Lilly-confirmed)
- FDA Priority Review: Obesity medications may qualify for expedited review
- FDA approval: If granted, most optimistic projection is late 2027
Important caveat: These are analyst projections, not FDA commitments. The approval process can be extended by requests for additional data, safety signals, or manufacturing review issues.
How Does Retatrutide Compare to Current Options?
For a detailed comparison, see:
In brief: if Phase 3 data holds and retatrutide is approved, it would represent the highest weight loss efficacy of any approved injectable anti-obesity medication — approximately 28.7% vs 22.5% for tirzepatide and 14.9% for semaglutide.
What Patients Should Know Now
Retatrutide is not available by prescription and cannot be obtained outside of registered clinical trials. Key points:
- No compounding: There is no approved retatrutide for compounding pharmacies to replicate — unlike semaglutide and tirzepatide, no branded version exists yet.
- No self-administration protocol: The investigational dosing schedule from clinical trials is not intended for use outside a supervised trial setting.
- Clinical trial enrollment: Eligible patients may be able to enroll in TRIUMPH trials via ClinicalTrials.gov. Discuss eligibility with your physician.
- Current best options: If you are interested in the most effective currently-approved option, tirzepatide (Zepbound) delivers 22.5% mean weight loss and is FDA-approved. See our Weight Loss Projector to estimate your expected outcomes.
Mechanism Deep Dive: Why Triple Agonism May Be a Step Change
The incremental value of adding glucagon receptor agonism to GIP/GLP-1 can be understood through three mechanisms:
1. Increased Energy Expenditure
Glucagon is a catabolic hormone that signals the body to burn fuel. In the liver, glucagon receptor activation promotes gluconeogenesis and fatty acid oxidation. In adipose tissue and muscle, it increases lipolysis. In combination with the appetite suppression from GLP-1, the net effect is both eating less AND burning more — a combination that single- and dual-agonists don't fully achieve.
2. Reduced Hepatic Fat
Glucagon receptor activation appears to be particularly potent at reducing hepatic steatosis (liver fat). This is clinically significant because MASH/NASH (metabolic dysfunction-associated steatohepatitis) is a common comorbidity in obesity. Phase 2 data showed meaningful reductions in liver fat with retatrutide.
3. Preserved Lean Mass?
A concern with all weight-loss medications is the proportion of fat vs lean mass lost. Preliminary data from retatrutide Phase 2 suggested that a higher proportion of weight lost was fat mass vs lean mass compared to some single-agent data — though this requires confirmation in Phase 3.
Expected Pricing (Speculative)
No pricing has been announced. Analysts generally expect retatrutide to be priced similarly to or above tirzepatide's current list price (~$1,086/month for Zepbound), given its superior efficacy profile. Manufacturer savings programs and insurance coverage dynamics will determine real-world patient cost.